Evaluating TBK1 as a therapeutic target in cancers with activated IRF3

• Published in: Molecular cancer research Vol. 12; no. 7; pp. 1055 - 1066
• Main Authors: Muvaffak, Asli, Pan, Qi, Yan, Haiyan, Fernandez, Rafael, Lim, Jongwon, Dolinski, Brian, Nguyen, Thi T, Strack, Peter, Wu, Stephen, Chung, Rossana, Zhang, Weiqun, Hulton, Chris, Ripley, Steven, Hirsch, Heather, Nagashima, Kumiko, Wong, Kwok-Kin, Jánne, Pasi A, Seidel-Dugan, Cynthia, Zawel, Leigh, Kirschmeier, Paul T, Middleton, Richard E, Morris, Erick J, Wang, Yan
• Format: Journal Article
• Language: English
• Published: United States 01.07.2014
• Subjects: Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - therapy; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factor-3 - antagonists & inhibitors; Interferon Regulatory Factor-3 - genetics; Interferon Regulatory Factor-3 - metabolism; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - therapy; Molecular Targeted Therapy; Neoplasms - genetics; Neoplasms - metabolism; Phosphorylation; Protein-Serine-Threonine Kinases - antagonists & inhibitors; Protein-Serine-Threonine Kinases - genetics; Protein-Serine-Threonine Kinases - metabolism; Signal Transduction
• ISSN: 1541-7786; 1557-3125
• DOI: 10.1158/1541-7786.MCR-13-0642

TBK1 (TANK-binding kinase 1) is a noncanonical IκB protein kinase that phosphorylates and activates downstream targets such as IRF3 and c-Rel and, mediates NF-κB activation in cancer. Previous reports demonstrated synthetic lethality of TBK1 with mutant KRAS in non-small cell lung cancer (NSCLC); thus, TBK1 could be a novel target for treatment of KRAS-mutant NSCLC. Here, the effect of TBK1 on proliferation in a panel of cancer cells by both genetic and pharmacologic approaches was evaluated. In KRAS-mutant cancer cells, reduction of TBK1 activity by knockdown or treatment with TBK1 inhibitors did not correlate with reduced proliferation in a two-dimensional viability assay. Verification of target engagement via reduced phosphorylation of S386 of IRF3 (pIRF3(S386)) was difficult to assess in NSCLC cells due to low protein expression. However, several cell lines were identified with high pIRF3(S386) levels after screening a large panel of cell lines, many of which also harbor KRAS mutations. Specifically, a large subset of KRAS-mutant pancreatic cancer cell lines was uncovered with high constitutive pIRF3(S386) levels, which correlated with high levels of phosphorylated S172 of TBK1 (pTBK1(S172)). Finally, TBK1 inhibitors dose-dependently inhibited pIRF3(S386) in these cell lines, but this did not correlate with inhibition of cell growth. Taken together, these data demonstrate that the regulation of pathways important for cell proliferation in some NSCLC, pancreatic, and colorectal cell lines is not solely dependent on TBK1 activity. TBK1 has therapeutic potential under certain contexts and phosphorylation of its downstream target IRF3 is a biomarker of TBK1 activity.